Coactivator SRC-2'dependent metabolic reprogramming mediates prostate cancer survival and metastasis

Journal of Clinical Investigation

Volumn 125, Issue 3, 2015, Pages 1174-1188

  Dasgupta, Subhamoy ^a   Putluri, Nagireddy ^a   Long, Weiwen ^a   Zhang, Bin ^a   Wang, Jianghua ^a   Kaushik, Akash K ^a   Arnold, James M ^a   Bhowmik, Salil K ^a   Stashi, Erin ^a   Brennan, Christine A ^b   Rajapakshe, Kimal ^a   Coarfa, Cristian ^a   Mitsiades, Nicholas ^a   Ittmann, Michael M ^a,c   Chinnaiyan, Arul M ^b,d,e   Sreekumar, Arun ^a   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; CITRIC ACID; GLUTAMINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NUCLEAR RECEPTOR COACTIVATOR 2; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; NCOA2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CARBOXYLATION; CELL METABOLISM; CITRIC ACID CYCLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIPOGENESIS; MALE; METABOLISM; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CELL SURVIVAL; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HELA CELL LINE; LUNG TUMOR; NUDE MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SCID MOUSE; SECONDARY;

ANIMALS; CELL SURVIVAL; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINE; HELA CELLS; HUMANS; LIPOGENESIS; LUNG NEOPLASMS; MALE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; NUCLEAR RECEPTOR COACTIVATOR 2; OXIDATION-REDUCTION; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84924049891     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76029     Document Type: Article

References (53)

1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
2. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012;2(10):881-898.
3. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297-308.
4. Metallo CM, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011;481(7381):380-384.
5. Mullen AR, et al. Reductive carboxylation supports growth in tumour cells with defective mito-chondria. Nature. 2011;481(7381):385-388.
6. Gao P,et al. C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism Nature. 2009,458, 7239, 762-765.
7. Wise DR, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48):18782-18787.
8. Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer. Biochim Biophys Acta. 2013;1831(10):1518-1532.
9. Rossi S, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1(10):707-715.
10. Fendt SM, et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013;73(14):4429-4438.
11. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763-777.
12. Currie E, Schulze A, Zechner R, Walther TC, Farese RV, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153-161.
13. Dasgupta S, Lonard DM, O'Malley BW. Nuclear receptor coactivators: master regulators of human health and disease. Annu Rev Med. 2014;65:279-292.
14. Chopra AR, et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science. 2008; 322(5906):1395-1399.
15. Chopra AR, et al. Cellular energy depletion resets whole-body energy by promoting coactivatormediated dietary fuel absorption. Cell Metab. 2011;13(1):35-43.
16. Picard F, et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell. 2002;111(7):931-941.
17. Stashi E, et al. SRC-2 is an essential coactivator for orchestrating metabolism and circadian rhythm. Cell Rep. 2014;6(4):633-645.
18. Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
19. Agoulnik IU, et al. Androgens modulate expression of tra nscription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006;66(21):10594-10602.
20. Dasgupta S, Srinidhi S, Vishwanatha JK. Oncogenic activation in prostate cancer progression and metastasis: molecular insights and future challenges. J Carcinog. 2012;11:4.
21. Duteil D, et al. The tr anscriptional coregulators TIF2 and SRC-1 regulate energy homeostasis by modulating mitochondrial respiration in skeletal muscles. Cell Metab. 2010;12(5):496-508.
22. Dasgupta S, Zhang B, Louet JF, O 'Malley BW. Steroid receptor coactivator-2 mediates oncogenic reprogramming of cancer cell metabolism. Cancer Res. 2012;72:5153.
23. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168(1):273-280.
24. Kosaka T, Miyajima A, Nagata H, Maeda T, Kikuchi E, Oya M. Human castration resistant prostate cancer rather prefer to decreased 5?-reductase activity. Sci Rep. 2013;3:1268.
25. Liu AY, et al. Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate. 2004;60(2):98-108.
26. Yoo H, Antoniewicz MR, Stephanopoulos G, Kelleher JK. Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. J Biol Chem. 2008;283(30):20621-20627.
27. Zhang J,Ahn WS,Gameiro PA,Keibler MA,Zhang Z,Stephanopoulos G 13C isotope-Assisted methods for quantifying glutamine metabolism in cancer cells Methods Enzymol. 2014 542 369-389.
28. Gameiro PA, et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013;17(3):372-385.
29. Wang Q, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 2007;27(3):380-392.
30. Seo YK, Chong HK, Infa nte AM, Im SS, Xie X, Osborne TF. Genome-wide analysis of SREBP-1 binding in mouse liver chromatin reveals a preference for promoter proximal binding to a new motif. Proc Natl Acad Sci U S A. 2009;106(33):13765-1 3769.
31. Kim JB, et al. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest. 1998;101(1):1-9.
32. Smolkov a K, Jezek P. The role of mitochondrial NADPH-dependent isocitrate dehydrogenase in cancer cells. Int J Cell Biol. 2012;2012:273947.
33. Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem. 1997;272(46):28875-28 881.
34. Singh KK, Desouki MM, Franklin RB, Costello LC. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer. 2006;5:14.
35. Duran RV, et al. Glutaminolysis activates RagmTORC1 signaling. Mol Cell. 2012;47(3):349-358.
36. Nicklin P, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521-534.
37. Han SJ, Lonard DM, O'Malley BW. Multi-modulation of nuclear receptor coactivators through posttranslational modifications. Trends Endocrinol Metab. 2009;20(1):8-15.
38. Kamphorst JJ, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A. 2013;110(22):8882-8887.
39. Peterson TR, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011;146(3):408-420.
40. Demirkan G, Yu K, Boylan JM, Salomon AR, Gruppuso PA. Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of rapamycin complex 1 (mTORC1). PLoS One. 2011;6(6):e21729.
41. Hsu PP, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332(6035):1317-1322.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
43. Dasgupta S, O'Malley BW. Transcriptional coregulators: emerging roles of SRC family of coactivators in disease pathology. J Mol Endocrinol. 2014;53(2):R47-R59.
44. Shukla K, et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem. 2012;55(23):10551-10563.
45. Jeong SM, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Ca ncer Cell. 2013;23(4):450-463.
46. Sreekumar A, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910-914.
47. DeBerardinis RJ, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104(49 ):19345-19350.
48. Csibi A, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2013;153(4):840-854.
49. Igal RA. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis. 2010;31(9):1509-1515.
50. Makhov P, Golovine K, Uzzo RG, Wuestefeld T, Scoll BJ, Kolenko VM. Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells. Gene. 2009;431(1):39-46.
51. Gehin M, Mark M, Dennefeld C, Dierich A, Gronemeyer H, Chambon P. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol. 2002;22(16):5923-5937.
52. Put luri N, et al. Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One. 2011;6(7):e21417.
53. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.